Table 1.
Targets and radioligands for phenotypic imaging of metastatic breast cancers.
| Molecular Target | Expression in Breast Cancer (%) | Theranostic Molecule | Clinical Trial | References |
|---|---|---|---|---|
| PARP | 45% | 18F-fluorthanatrace | Yes | [84] |
| Gastrin-Releasing | 75.8% | 68Ga-NeoBOMB1 | Yes | [68] |
| Peptide Receptor | 177Lu-NeoBOMB1 | Yes | ||
| PSMA | 60% | 68Ga-PSMA-617 | Yes | [71,85,86] |
| 177Lu-PSMA-617 | Yes | |||
| PD-1/PD-L1 | 29% to 50% | 89Zr-Pembrolizumab | Yes (Phase II) | [87] |
| 89Zr-Atezolizumab | Yes (Phase I) | |||
| 18F or 89Zr-Adnectin | Yes (Feasibility) | |||
| 99mTc-Nb | Yes (Phase I) | |||
| CXCR-4 | 56% | 68Ga-Pentixafor | Yes | [88] |
| Mesothelin | 30% | 89Zr-mAb (MM0T0530A) | Phase I | [89,90,91] |
| 111In-Amatuximab | Phase I | |||
| 99mTc-A1 | No |